CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WI…

Emerging

4
Citations
0
Refs
2020
Year
Search Works
Work Details
  • DOI 10.1097/01.tp.0000698592.29821.e5
  • OpenAlex ID W3081737798
  • Type Article
  • Language EN
  • Published 28 Aug 2020
  • Volume 104 (S3)
  • Pages S67–S68
  • Source Transplantation
  • Publisher Wolters Kluwer
  • FWCI 0.64
  • Countries 1
  • Institutions 1
  • Added 08 Sep 2020
  • Updated 14 Oct 2026
External Links
OpenAlex Record DOI Resolver
MENU
0

CLAZAKIZUMAB (ANTI-IL-6 MONOCLONAL) TREATMENT OF PATIENTS WITH CHRONIC & ACTIVE ANTIBODY-MEDIATED REJECTION POST-KIDNEY TRANSPLANTATION (NCT03380377)

Article 2020 EN

Introduction: Highly sensitized (HS) patients are at an increased risk for chronic antibody mediated rejection (cABMR) and graft loss due to persistent, deleterious DSA production. Therapeutic options currently available to prevent and treat cABMR are limited. Here, we report our updated, 18 month experience using clazakizumab, a novel anti-IL-6 monoclonal, in HS patients with cABMR + transplant g…

4

Citations

0

References

15

Authors

0.64

FWCI

Citations by Year
Last 4 years
Topics
Keywords
UN Sustainable Development Goals
1 SDGs
Authors & Affiliations
15 authors
#AuthorInstitutionsORCID
1 Stanley C. Jordan Cedars-Sinai Medical Center (US)
2 Noriko Ammerman Cedars-Sinai Medical Center (US)
3 Mieko Toyoda Cedars-Sinai Medical Center (US)
4 Shili Ge Cedars-Sinai Medical Center (US) —
5 Edmund Huang Cedars-Sinai Medical Center (US)
6 Alice Peng Cedars-Sinai Medical Center (US)
7 Supreet Sethi Cedars-Sinai Medical Center (US)
8 Reiad Najjar Cedars-Sinai Medical Center (US)
9 Edwin Ortiz Cedars-Sinai Medical Center (US) —
10 Maggie Chu Cedars-Sinai Medical Center (US) —
11 Abner De Guzman Cedars-Sinai Medical Center (US) —
12 Irene K. Kim Cedars-Sinai Medical Center (US)
13 Kathlyn Lim Cedars-Sinai Medical Center (US)
14 Jua Choi Cedars-Sinai Medical Center (US)
15 Ashley A. Vo Cedars-Sinai Medical Center (US)
Related Works
10

Data: OpenAlex